Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients

Phase 2

• Conditions: GBM
• Interventions: Drug: Chlorogenic acid for Injection; Drug: Lomustine

• Registration Number: NCT03758014
• Lead Sponsor: Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd

Brief Summary

The purpose of phase II/III study: Determining the Overall Survival（OS）of Chlorogenic acid for injection comparing to in the advanced Glioblastoma Patients through study completion（an average of 18 months）after the first dose of chlorogenic acid for injection and Lomustine.

Detailed Description

Chlorogenic acid (CHA) is a class 1 innovative small molecular natural drug, developed by Sichuan Jiuzhang Biological Science and Technology Co., Ltd. The mechanism of broad-spectrum antitumor activity is immunoregulation. After received the clinical trial approval issued by CFDA, Jiuzhang Biotech successfully finished the phase I clinical studies of CHA for injection in advanced GBM patients, focus on safety, PK, and preliminary efficacy evaluation.

The results of phase I data showed that CHA had good safety, the main adverse effect was induration, no other serious adverse effects. PK exhibited that CHA had a rapid metabolism character (t1/2 = 1-1.5 h). In addition, there were no accumulative side effects for long-term use. To the investigators' surprise, the preliminary efficacy evaluation was amazing, there were 1 case CR and 1 case PR. The median OS of grade IV GBM patients was 21.4 months in effective dose group, which was much better than that of the historical reported data.The purpose of phase II/III study: Determining the Overall Survival（OS）of Chlorogenic acid for injection comparing to in the advanced Glioblastoma Patients through study completion（an average of 18 months）after the first dose of chlorogenic acid for injection and Lomustine .

Study Timeline

• Study First Submitted: 2018-10-21
• Status Verified: 2018-11
• Study Start: 2018-11-27
• Study First Submitted QC: 2018-11-27
• Last Update Submitted: 2018-11-27
• Study First Posted: 2018-11-29
• Last Update Posted: 2018-11-29
• Primary Completion: 2020-10-30
• Study Completion: 2021-04-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Age ≥ 18;
2. KPS ≥ 60;
3. Recurrent GBM;
4. Estimated lifetime ≥ 3 months；
5. Female patients with negative pregnant test, and male/female patients of reproductive age without pregnancy planning in the next 12 months;
6. Volunteered for the phase 2 trial and sign the informed consent without protest.

Exclusion Criteria

1. Patients who have received the therapy of chemotherapy or radical radiotherapy within 1 month before enrollment;
2. Pregnant or breast-feeding women, or patients(male and female) who have pregnancy plan;
3. Patients who had received a therapy of another investigational drug within 1 month；
4. Known active hepatitis B/hepatitis C, positive HIV/ syphilis antibody;
5. Patients who have received therapy of major surgery within 4 weeks or biopsy surgery within 1 week before enrollment;
6. Patient who need long term treatment of cortical hormone or other immunosuppressive drugs such as visceral organ transplanters；
7. Patients who have sufficient baseline organ function and whose laboratory data can meet the following criteria at the enrollment:1)PLT count<80×10~9/L； 2)NEUT# count<1.5×10~9/L ；3)HGB count<90g/L；4)Total bilirubin >1.5 times of ULN；5)ALT/AST >1.5 times of ULN；
8. History of drug abuse；
9. Patients who was treated with Immunologic drugs（DC/CIK/CTL/PD-（L）1） in 3 months;
10. Patients who are false progressers；
11. Patients who can not be received MRI examination；
12. Patients who had severe trauma or infectious diseases within 4 weeks；
13. Patients who had cerebral stroke or Transient ischemic attack within 6 months；
14. Patients who were performed important operations within 4 weeks；
15. Uncontrollable psychopaths;
16. Patients who had other advanced cancers within 5 years；
17. Patients who had grade III or IV heart failure within 6 months；
18. Other patients judged ineligible for enrollment in the study by the investigator (sub-investigator).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Chlorogenic Acid for Injection	Chlorogenic acid for Injection	3 mg/kg per day, injection for 28 days，5 weeks per circle; max. 8 circles
Lomustine	Lomustine	110 mg/m2 taken as a single oral dose every 6 weeks; max. 4 circles

Primary Outcome Measures

Name	Time	Method
Overall Survival（OS）	Through study completion（an average of 18 months）after the first dose of chlorogenic acid for injection and Lomustine

Secondary Outcome Measures

Name	Time	Method
progress free survival(PFS)	Through study completion（an average of 18 months）after the first dose of chlorogenic acid for injection and Lomustine
disease control rate（DCR)	Within the first 10 weeks after the first dose of chlorogenic acid for injection and Lomustine
objective response rate (ORR)	Within the first 10 weeks after the first dose of chlorogenic acid for injection and Lomustine
Karnofsky score standard	Through study completion（an average of 18 months）after the first dose of chlorogenic acid for injection and Lomustine
Montreal Cognitive Assessment score standard	Through study completion（an average of 18 months）after the first dose of chlorogenic acid for injection and Lomustine

Trial Locations

Locations (1)

Beijing Tiantan Hospital, Capital Medical University; 🇨🇳 Beijing, Beijing, China